Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832899 | 0.95 | CDK4 (0.42) | CDK4CDK6EGFR | |
| SCHEMBL5832102 | 0.87 | CCNK (0.47) | CDK6EGFR | |
| SCHEMBL5832235 | 0.83 | CHRNB4 (0.43) | CDK4CDK6 | |
| SCHEMBL5832698 | 0.83 | CHRNB4 (0.40) | CDK4CDK6EGFR | |
| SCHEMBL5832383 | 0.82 | CDK6 (0.46) | CDK4CDK6EGFR | |
| SCHEMBL5832959 | 0.79 | DEGS1 (0.45) | — | |
| SCHEMBL5832667 | 0.79 | CDK4 (0.44) | CDK4CDK6 | |
| SCHEMBL5832799 | 0.79 | CDK4 (0.42) | CDK4CDK6 | |
| SCHEMBL5832936 | 0.79 | CHRNB2 (0.40) | — | |
| SCHEMBL5832425 | 0.79 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | claimed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | claimed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | claimed |
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | BPTF 3009/4885CDK4 1316/4885CDK6 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.